02 Jun 2016 Adocia to Present at the Jefferies 2016 Global Healthcare Conference Icon check
31 May 2016 Adocia and Lilly announce positive topline results from a Phase 1 study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Icon check
13 May 2016 Adocia to hold its annual shareholders’ meeting on June 21, 2016 in Paris Icon check
03 May 2016 Adocia strengthens its BioChaperone Combo patent portfolio Icon check
27 Apr 2016 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro U100 in people with type 2 diabetes Icon check
14 Apr 2016 Adocia announces first quarter 2016 results Icon check
11 Apr 2016 Adocia Initiates a Phase 1/2 Clinical Trial on the Post-Meal Effect of Rapid-Acting Human Insulin, HinsBet® U100 Icon check
11 Apr 2016 Adocia announces the release of its Reference Document, for the year 2015 Icon check
25 Mar 2016 ADOCIA confirms its eligibility for the PEA – PME Icon check
21 Mar 2016 Adocia Welcomes Internationally Renowned Diabetes Experts to Inaugural Medical Advisory Board Icon check
16 Mar 2016 Annual Financial Results 2015 Icon check
14 Mar 2016 Adocia and Lilly announce positive topline results from a Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
16 Feb 2016 ADOCIA announced significant revenue growth with EUR 36.9 million (EUR 0.7 million in 2014) in revenue and a solid cash position of EUR 72 million as of December 31, 2015 Icon check
04 Feb 2016 Adocia to Present at the 2016 Leerink Global Healthcare Conference Icon check
29 Jan 2016 Adocia and Lilly initiate Phase 1b study evaluating ultra-rapid insulin BioChaperone Lispro U100 in healthy Japanese subjects Icon check
08 Jan 2016 Half year report on Adocia’ s liquidity agreement with Kepler Capital Markets Icon check
16 Dec 2015 Adocia announces its financial calendar for 2016 Icon check
15 Dec 2015 Adocia to Hold Conference Call For Investors to Provide 2015 Annual Business Update and Perspectives For 2016 Icon check
11 Dec 2015 Adocia and Lilly report positive results of a pilot bioequivalence study comparing BioChaperone Lispro U200 to BioChaperone Lispro U100 Icon check
25 Nov 2015 Adocia announces positive Phase 1b results of BioChaperone® Combo in patients with type 2 diabetes Icon check
19 Nov 2015 Adocia receives the Deloitte In Extenso Technology Fast 50 Prize in the “Listed Company” category for the Grand Rhône-Alpes region Icon check
04 Nov 2015 Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 diabetes Icon check
13 Oct 2015 ADOCIA Reports Third Quarter 2015 Financial Results Icon check
06 Oct 2015 Adocia and Lilly initiate a Phase 1b study evaluating ultra-rapid BioChaperone Lispro in patients with type 1 diabetes using insulin pump therapy Icon check
05 Oct 2015 Adocia to hold an extraordinary shareholders’ meeting on November 12, 2015 in Lyon Icon check
30 Sep 2015 Adocia and Lilly initiate a new Phase 1b study of repeat administration of ultra-rapid BioChaperone Lispro in patients with type 2 diabetes Icon check
17 Sep 2015 ADOCIA: additional contribution to the liquidity agreement Icon check
27 Aug 2015 Adocia and Lilly initiate new Phase 1b study of repeated administration of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
21 Jul 2015 Adocia presents financial results for the first half of 2015 highlighting strong growth Icon check
10 Jul 2015 Adocia initiates two clinical studies on its combination of long-acting insulin glargine and fast-acting insulin lispro, BioChaperone® Combo
26 Jun 2015 Adocia and Lilly report positive Phase 1b topline results on the post-meal effect of ultra-rapid BioChaperone Lispro in patients with type 1 diabetes Icon check
15 Jun 2015 Adocia is now integrated into the CAC Mid 60 and SBF 120 Indices Icon check
05 Jun 2015 “Ultra-Rapid BioChaperone® Insulin Lispro (BC LIS): Linear Dose-Response and Faster Absorption than Insulin Lispro (LIS)” (Poster 979), presented by Dr. Grit Anderson, 75th Scientific Sessions of the American Diabetes Association, 5-9 June 2015, Boston, MA (USA)
28 May 2015 Adocia to Present Positive Clinical Results for BioChaperone® Lispro at the American Diabetes Association 75th Scientific Sessions on June 6th 2015 Icon check
26 May 2015 Adocia to Present at the Jefferies 2015 Global Healthcare Conference in New-York City (USA) Icon check
04 May 2015 Adocia announces the release of its Reference Document, containing the Annual Financial Report, for the year 2014 Icon check
29 Apr 2015 Adocia is now integrated into the EnterNext Tech 40 Index Icon check
20 Apr 2015 Adocia to hold its annual shareholders’ meeting on May 27, 2015 in Lyon Icon check
14 Apr 2015 Adocia announces first quarter 2015 results Icon check
16 Mar 2015 Adocia will present its 2014 annual results and its perspectives of growth during a conference call Icon check
10 Mar 2015 Adocia reports a strengthened cash position and intensifies clinical development Icon check
05 Mar 2015 Adocia opens a subsidiary in the USA and is pleased to appoint Simon Bruce, MD and Stephen Daly Icon check
17 Feb 2015 ADOCIA: annual revenue and net cash position for 2014 Icon check
10 Feb 2015 Adocia: modification of the means allocated to the liquidity agreement Icon check
05 Feb 2015 Adocia reports positive results from phase IIa clinical study of fast-acting human insulin, HinsBet Icon check
20 Jan 2015 Adocia initiates a clinical study on the post-meal effect of ultra-rapid BioChaperone Lispro insulin formulation Icon check
09 Jan 2015 Half year report on Adocia’s liquidity agreement with Kepler Capital Markets Icon check
29 Dec 2014 ADOCIA announces its financial calendar for 2015 Icon check
22 Dec 2014 ADOCIA: shareholder newsletter and invitation to two conference calls today and tomorrow Icon check
19 Dec 2014 Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology Icon check
Join our mailing list. Subscribe